Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

References

• Kreuter M, Swigris JJ, Pittrow D, et al. Quality of life (QOL) trajectory in patients with idiopathic pulmonary fibrosis (IPF): longitudinal QOL assessment of the INSIGHTS-IPF registry. Am J Respir Crit Care Med. 2017;195:A1128.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, IPF Consensus Working Group, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692.
   PubMed Web of Science ®Google Scholar
• Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. Respirology. 2016;21:259–268.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Bendstrup E, Wells AU, et al. Unclassifiable interstitial lung diseases: clinical characteristics and survival. Respirology. 2017;22:494–500.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76:1700–1706.
   PubMed Web of Science ®Google Scholar
• Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146:422–436.
   PubMed Web of Science ®Google Scholar
• Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10:362–370.
   PubMedGoogle Scholar
• Fernández Pérez ER, Swigris JJ, Forssén AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644–1651.
   PubMed Web of Science ®Google Scholar
• Khalil N, Churg A, Muller N, et al. Environmental, inhaled and ingested causes of pulmonary fibrosis. Toxicol Pathol. 2007;35:86–96.
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4:e000212.
   PubMed Web of Science ®Google Scholar
• Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18:275.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518–2528.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–19.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620–628.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327–1339.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Walscher J, Behr J. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Curr Opin Pulm Med. 2017;23:418–425.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Herth FJF, Witt S, et al. Diagnosis and management of patients with interstitial lung disease (ILD) in clinical practice in Germany: EXCITING-ILD registry. American Thoracic Society 2018 International Conference, 2018 May 18–23, San Diego.
   Google Scholar
• Fisher JH, Shapera S, Algamdi M, et al. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. American Thoracic Society 2018 International Conference, 2018 May 18–23, San Diego.
   Google Scholar
• Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Rev. 2014;23:225–230.
   PubMedGoogle Scholar
• Purokivi M, Hodgson U, Myllärniemi M, et al. Are physicians in primary health care able to recognize pulmonary fibrosis?. Eur Clin Respir J. 2017;4:1290339.
   PubMed Web of Science ®Google Scholar
• Fischer A, Richeldi L. Cross-disciplinary collaboration in connective tissue disease-related lung disease. Semin Respir Crit Care Med. 2014;35:159–165.
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–1254.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–1328.
   PubMed Web of Science ®Google Scholar
• Kim MY, Song JW, Do KH, et al. Idiopathic nonspecific interstitial pneumonia: changes in high-resolution computed tomography on long-term follow-up. J Comput Assist Tomogr. 2012;36:170–174.
   PubMed Web of Science ®Google Scholar
• Mooney JJ, Elicker BM, Urbania TH, et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013;144:586–592.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42:750–757.
   PubMed Web of Science ®Google Scholar
• Gimenez A, Storrer K, Kuranishi L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018;73:391–392.
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest. 2017;152:1283–1295.
   PubMed Web of Science ®Google Scholar
• Adegunsoye A, Oldham JM, Chung JH, et al. Phenotypic clusters predict outcomes in a longitudinal interstitial lung disease cohort. Chest. 2018;153:349–360.
   PubMed Web of Science ®Google Scholar
• Assayag D, Lubin M, Lee JS, et al. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014;19:493–500.
   PubMed Web of Science ®Google Scholar
• Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest. 2018;153:105–113.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017;69:542–549.
   PubMed Web of Science ®Google Scholar
• Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137:129–137.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140:221–229.
   PubMed Web of Science ®Google Scholar
• Maher TM, Molina-Molina M, Russell AM, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med. 2017;17:124.
   PubMed Web of Science ®Google Scholar
• Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease – individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20:17.
   PubMed Web of Science ®Google Scholar
• Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70:1820–1828.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2666.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708–719.
   PubMed Web of Science ®Google Scholar
• Khanna D, Strek M, Southern M, et al. Expert consensus on the screening, treatment, and management of patients with systemic sclerosis-interstitial lung disease, and the potential role of anti-fibrotics in a treatment paradigm for systemic sclerosis-interstitial lung disease: a Delphi consensus study. Arthritis Rheumatol. 2018;70(Suppl 9):1–3584.
   Google Scholar
• Schwarzkopf L, Witt S, Waelscher J, et al. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis. Respir Res. 2018;19:73.
   PubMed Web of Science ®Google Scholar